---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-268497"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T12:26:43.139912+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest

## Summary
- Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.
- XOMA gets low- to mid-single-digit net royalty on seralutinib commercial sales.
- XOMA retains up to $25M of future milestone payments tied to seralutinib.
- Seralutinib (Phase 3 PAH) readout expected Q4 2025; developed by Gossamer/Chiesi.
- This is XOMA's second whole-company acquisition in 2024.

## SEC filing metadata
- accession: 0001193125-24-268497
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524268497/0001193125-24-268497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524268497/d900185d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-268497
- JSON: https://secwatch.observer/filing/0001193125-24-268497.json
- Plain text: https://secwatch.observer/filing/0001193125-24-268497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.